Rashtriya Newsflash

HER2-Negative Breast Cancer – Pipeline Insight, 2026

DelveInsight’s “HER2-Negative Breast Cancer – Pipeline Insight, 2026” report provides comprehensive insights about 70+ companies developing several pipeline drugs in the HER2-Negative Breast Cancer pipeline landscape. It covers the HER2-Negative Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the HER2-Negative Breast Cancer treatment landscape. Learn more about the evolving HER2-Negative Breast Cancer pipeline today @ https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr

Key Takeaways from the HER2-Negative Breast Cancer Pipeline Report

• On April 13, 2026, Merck Sharp & Dohme LLC initiated a Phase 3 study in triple-negative breast cancer (TNBC) and hormone receptor (HR)-low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer.

• On April 08, 2026, Daiichi Sankyo announced a study to evaluate the safety and efficacy of trastuzumab deruxtecan (T-DXd) in participants with HER2-low or HER2 immunohistochemistry (IHC) 0 unresectable and/or metastatic breast cancer.

• On April 06, 2026, Beijing Biotech conducted a Phase 1/2 study to test the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer.

• On October 6, 2025, AstraZeneca’s datopotamab deruxtecan (Dato-DXd) demonstrated significant improvement in overall survival as a first-line therapy for patients with metastatic triple-negative breast cancer in the TROPION-Breast02 trial.

• HER2-negative breast cancer cells contain little to no HER-2 protein, causing them to grow more slowly and offering a different outlook compared to HER2-positive cancers.

• The pipeline landscape for HER2-negative breast cancer features over 70 companies rigorously developing more than 70 pipeline therapies across multiple clinical stages.

• AstraZeneca holds a leading position in this space, with clinical candidates such as camizestrant currently being evaluated in Phase III trials.

• Leading HER2-Negative Breast Cancer companies include Merck Sharp & Dohme LLC, AstraZeneca, Roche, Genentech, Daiichi Sankyo, Novartis, Beijing Biotech, and Regor Therapeutics.

• Promising therapies under development include small molecules like giredestrant and inavolisib, antibody-drug conjugates (ADCs) like datopotamab deruxtecan, and novel CDK inhibitors like RGT-419B.

Download for updates and the latest revolution in HER2-negative breast cancer care @ HER2-Negative Breast Cancer Market Insight, Epidemiology And Market Forecast

HER2-Negative Breast Cancer Emerging Drugs Profile

Giredestrant: Roche / Genentech

Giredestrant is a novel investigative small molecule that serves as a selective estrogen receptor degrader (SERD). Administered orally, it competitively inhibits the binding of estrogen to the estrogen receptor (ER), immobilizing both wild-type and mutant ER and attenuating the expression of target genes. Preclinical models have shown that giredestrant is orally bioavailable and restrains the dynamic behavior of the ER to inhibit tumor cell proliferation.

Inavolisib: Roche / Genentech

Inavolisib is an investigational oral small molecule designed to selectively inhibit mutant PI3Kα. It binds to the ATP-binding site of PI3Kα, blocking the phosphorylation of PIP2 to PIP3 and preventing downstream signaling. Inavolisib specifically degrades the mutant form of PI3Kα, resulting in a reduction of pathway activity, and has shown increased potency toward mutant PI3K cells over wild-type cells in preclinical models.

Camizestrant: AstraZeneca

Camizestrant is a potent, next-generation oral SERD and pure ERα antagonist. It has demonstrated anti-cancer activity across a range of preclinical models, including those harboring ER-activating mutations. The asset has shown a promising anti-tumor profile both as a monotherapy and in combination with other agents, leading to its current evaluation in Phase III clinical trials for breast cancer.

For more information on the HER2-Negative Breast Cancer Emerging Drugs Profile, download DelveInsight’s comprehensive HER2-Negative Breast Cancer Pipeline Insight report.

The HER2-Negative Breast Cancer Pipeline Report Provides

• Detailed insights about companies developing therapies for HER2-Negative Breast Cancer, with aggregate therapies developed by each company.

• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for treatment.

• Companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Drugs under development based on stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecular type.

• Detailed analysis of collaborations, licensing agreements, and financing details for future advancement of the HER2-Negative Breast Cancer market.

Learn more about HER2-Negative Breast Cancer drug opportunities in our comprehensive pipeline report @ HER2-Negative Breast Cancer Unmet Needs

HER2-Negative Breast Cancer Companies and Competitive Landscape

There are 70+ key companies, including Merck Sharp & Dohme LLC, AstraZeneca, Roche, Genentech, Daiichi Sankyo, Novartis, Beijing Biotech, and Regor Therapeutics, developing therapies for HER2-Negative Breast Cancer, with AstraZeneca leading with advanced drug candidates in Phase III trials.

DelveInsight’s HER2-Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:

• Oral

• Parenteral

• Intravitreal

• Subretinal

• Topical

HER2-Negative Breast Cancer products have been categorized under various Molecule types such as:

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Discover the latest advancements in HER2-Negative Breast Cancer treatment by visiting our website. Stay informed @ HER2-Negative Breast Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the HER2-Negative Breast Cancer Pipeline Report

• Coverage: Global

• HER2-Negative Breast Cancer Companies: AstraZeneca, Roche, Genentech, Merck Sharp & Dohme LLC, Daiichi Sankyo, Novartis, Beijing Biotech, and others.

• HER2-Negative Breast Cancer Therapies: Camizestrant, Giredestrant, Inavolisib, Datopotamab deruxtecan, RGT-419B, and other pipeline candidates.

• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Table of Contents

1. Introduction

2. Executive Summary

3. HER2-Negative Breast Cancer: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. HER2-Negative Breast Cancer – DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III)

8. Mid Stage Products (Phase II)

9. Early Stage Products (Phase I)

10. Preclinical and Discovery Stage Products

11. Inactive Products

12. HER2-Negative Breast Cancer Key Companies

13. HER2-Negative Breast Cancer Key Products

14. HER2-Negative Breast Cancer Unmet Needs

15. HER2-Negative Breast Cancer Market Drivers and Barriers

16. HER2-Negative Breast Cancer Future Perspectives and Conclusion

17. HER2-Negative Breast Cancer Analyst Views

18. Appendix

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services